000			02275 a2200601 4500
005			20250516192109.0
264		0	_c20140414
008			201404s 0 0 eng d
022			_a1550-6606
024	7		_a10.4049/jimmunol.1302954 _2doi
040			_aNLM _beng _cNLM
100	1		_aBaig, Nisar A
245	0	0	_aInduced resistance to ofatumumab-mediated cell clearance mechanisms, including complement-dependent cytotoxicity, in chronic lymphocytic leukemia. _h[electronic resource]
260			_bJournal of immunology (Baltimore, Md. : 1950) _cFeb 2014
300			_a1620-9 p. _bdigital
500			_aPublication Type: Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
650	0	4	_aAdult
650	0	4	_aAged
650	0	4	_aAged, 80 and over
650	0	4	_aAlemtuzumab
650	0	4	_aAntibodies, Monoclonal _xblood
650	0	4	_aAntibodies, Monoclonal, Humanized _xtherapeutic use
650	0	4	_aAntigens, CD _xbiosynthesis
650	0	4	_aAntigens, CD20 _xbiosynthesis
650	0	4	_aAntigens, Neoplasm _xbiosynthesis
650	0	4	_aAntineoplastic Agents _xtherapeutic use
650	0	4	_aAntineoplastic Combined Chemotherapy Protocols _xtherapeutic use
650	0	4	_aB-Lymphocytes _xcytology
650	0	4	_aCD52 Antigen
650	0	4	_aComplement System Proteins _xmetabolism
650	0	4	_aCyclophosphamide _xtherapeutic use
650	0	4	_aCytotoxicity, Immunologic _ximmunology
650	0	4	_aDrug Resistance, Neoplasm
650	0	4	_aFemale
650	0	4	_aGlycoproteins _xbiosynthesis
650	0	4	_aHumans
650	0	4	_aLeukemia, Lymphocytic, Chronic, B-Cell _xdrug therapy
650	0	4	_aLymphocyte Count
650	0	4	_aMale
650	0	4	_aMiddle Aged
650	0	4	_aPentostatin _xtherapeutic use
650	0	4	_aTreatment Outcome
700	1		_aTaylor, Ronald P
700	1		_aLindorfer, Margaret A
700	1		_aChurch, Amy K
700	1		_aLaPlant, Betsy R
700	1		_aPettinger, Adam M
700	1		_aShanafelt, Tait D
700	1		_aNowakowski, Grzegorz S
700	1		_aZent, Clive S
773	0		_tJournal of immunology (Baltimore, Md. : 1950) _gvol. 192 _gno. 4 _gp. 1620-9
856	4	0	_uhttps://doi.org/10.4049/jimmunol.1302954 _zAvailable from publisher's website
999			_c23455295 _d23455295